Literature DB >> 11862316

Apolipoprotein E gene promoter (-219G/T) polymorphism is associated with premature coronary heart disease.

L Viitanen1, J Pihlajamäki, R Miettinen, P Kärkkäinen, I Vauhkonen, P Halonen, A Kareinen, S Lehto, M Laakso.   

Abstract

The relationship of two apolipoprotein (apo) E gene polymorphisms and coronary heart disease (CHD) was investigated in 118 Finnish families with premature CHD and in 110 healthy control subjects. Affected siblings and probands with premature CHD had higher frequencies of the T allele of the -219G/T promoter polymorphism and the epsilon 4 allele (genotypes epsilon 4/3 or epsilon 4/4) of the apo epsilon 2/epsilon 3/ epsilon 4 polymorphism than those of healthy control subjects. Additionally, when the two apo E gene polymorphisms were combined, affected siblings and probands had a higher frequency of the -219T allele and the epsilon 4 allele combinations than did healthy controls. The -219T and the epsilon 4 alleles both separately and together were associated with higher levels of 2-h glucose in an oral glucose tolerance test. These results indicate that the two polymorphisms of the apo E gene have similar effects on the risk of coronary atherosclerosis in families with premature CHD. This risk was not explained by the effect of apo E gene polymorphisms on cholesterol metabolism, but their effect on cardiovascular risk factor clustering with insulin resistance may be of importance. We conclude that in addition to the epsilon 4 allele, also the -219G/T promoter polymorphism of the apo E gene is associated with early onset CHD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11862316     DOI: 10.1007/s001090100265

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  10 in total

Review 1.  Genetics, the environment, and lipid abnormalities.

Authors:  Jose M Ordovas; And Haiqing Shen
Journal:  Curr Cardiol Rep       Date:  2002-11       Impact factor: 2.931

2.  Is there a relation between APOE expression and brain amyloid load in Alzheimer's disease?

Authors:  J-C Lambert; D Mann; F Richard; J Tian; J Shi; U Thaker; S Merrot; J Harris; B Frigard; T Iwatsubo; C Lendon; P Amouyel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-07       Impact factor: 10.154

3.  Specific interaction of heterogeneous nuclear ribonucleoprotein A1 with the -219T allelic form modulates APOE promoter activity.

Authors:  Mónica Campillos; José Ramón Lamas; Miguel Angel García; María Jesús Bullido; Fernando Valdivieso; Jesús Vázquez
Journal:  Nucleic Acids Res       Date:  2003-06-15       Impact factor: 16.971

Review 4.  The key role of apolipoprotein E in atherosclerosis.

Authors:  Kirsty Greenow; Nigel J Pearce; Dipak P Ramji
Journal:  J Mol Med (Berl)       Date:  2005-04-13       Impact factor: 4.599

5.  APOE/C1/C4/C2 gene cluster genotypes, haplotypes and lipid levels in prospective coronary heart disease risk among UK healthy men.

Authors:  Gie Ken-Dror; Philippa J Talmud; Steve E Humphries; Fotios Drenos
Journal:  Mol Med       Date:  2010-05-20       Impact factor: 6.354

6.  Variation in 5' promoter region of the APOE gene contributes to predicting ischemic heart disease (IHD) in the population at large: the Copenhagen City Heart Study.

Authors:  J H Stengård; R Frikke-Schmidt; A Tybjaerg-Hansen; B G Nordestgaard; C F Sing
Journal:  Ann Hum Genet       Date:  2007-05-29       Impact factor: 1.670

7.  Expression analysis, single nucleotide polymorphisms and combined genotypes in candidate genes and their associations with growth and carcass traits in Qinchuan cattle.

Authors:  Li-jun Wang; Xiao-lin Liu; Hong-liang Wang; Hua He; Zhi-xiong Li; Ling Chen
Journal:  Mol Biol Rep       Date:  2012-11-30       Impact factor: 2.316

8.  Genetic variants modify the effect of age on APOE methylation in the Genetics of Lipid Lowering Drugs and Diet Network study.

Authors:  Yiyi Ma; Caren E Smith; Chao-Qiang Lai; Marguerite R Irvin; Laurence D Parnell; Yu-Chi Lee; Lucia Pham; Stella Aslibekyan; Steven A Claas; Michael Y Tsai; Ingrid B Borecki; Edmond K Kabagambe; Silvia Berciano; José M Ordovás; Devin M Absher; Donna K Arnett
Journal:  Aging Cell       Date:  2014-12-04       Impact factor: 9.304

9.  Comprehensive evaluation of the association of APOE genetic variation with plasma lipoprotein traits in U.S. whites and African blacks.

Authors:  Zaheda H Radwan; Xingbin Wang; Fahad Waqar; Dilek Pirim; Vipavee Niemsiri; John E Hokanson; Richard F Hamman; Clareann H Bunker; M Michael Barmada; F Yesim Demirci; M Ilyas Kamboh
Journal:  PLoS One       Date:  2014-12-12       Impact factor: 3.240

10.  Influence of CYP4F2, ApoE, and CYP2A6 gene polymorphisms on the variability of Warfarin dosage requirements and susceptibility to cardiovascular disease in Jordan.

Authors:  Laith N Al-Eitan; Ayah Y Almasri; Adan H Alnaamneh; Hatem A Aman; Nasr N Alrabadi; Rame H Khasawneh; Mansour A Alghamdi
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.